Idiopathic Membranous Nephropathy
Conditions
Keywords
Idiopathic Membranous Nephropathy, Traditional Chinese Medicine, Randomized Control Trial
Brief summary
The purpose of this study is to evaluate the clinical safety and efficacy of QingReMoShen Granule to treat idiopathic membranous nephropathy.
Interventions
DRUGLosartan Tablets & QingReMoShen Granule
DRUGLosartan Tablets & Placebo Granule
Sponsors
wanglin
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Women and men who had a clinic and biopsy-proven idiopathic membranous nephropathy; * 6.0g≥24 hour urinary protein≥1.0g; * serum albumin concentration≥26g/L; * Chronic Kidney Disease (CKD)≤3 stage (eGFR\>30ml/min/1.73m2 MDRD); * Willing to participate in the trial and signed an informed consent.
Exclusion criteria
* Secondary membranous nephropathy; * Patients with one of the following circumstances- malignant tumors or malignancy, HIV infection, a history of mental illness, any serious systemic infection, serious gastrointestinal diseases, circulating hepatitis B surface antigens positive or persistent abnormal serum transaminase, abnormal glucose metabolism or diabetes mellitus; * Pregnant and lactating women; * Undergoing other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour urine protein | At the 24thweek |
Secondary
| Measure | Time frame |
|---|---|
| serum albumin concentration | At the 24thweek |
| eGFR | At the 24thweek |
| Alanine transaminase | At the 24thweek |
Other
| Measure | Time frame | Description |
|---|---|---|
| T-cell classification | At the 24thweek | Detecting by flow cytometry method |
Countries
China
Outcome results
None listed